Avila Therapeutics
100 Beaver Street
Waltham
Massachusetts
United States
Tel: 781-891-0086
Fax: 781-891-0069
Website: http://www.avilatx.com/
Email: info@avilatx.com
43 articles about Avila Therapeutics
-
Cedilla Therapeutics Expands Leadership Team with New Appointments to Direct Biology, Drug Discovery and Proteomics
6/28/2018
Cedilla Therapeutics today formally announced the appointment of three vice presidents with extensive experience in drug discovery to advance the company’s mission of harnessing existing protein stability mechanisms to redirect the course of disease.
-
Genome-Editing Company Editas Medicine Brings In Ex-Avila Therapeutics CEO For Top Post
6/24/2014
-
Celgene Corporation Completes Acquisition of Avila Therapeutics
3/8/2012
-
Celgene Acquisition of The Leukemia & Lymphoma Society Partner, Avila Therapeutics, Significant Advance for Novel Blood Cancer Therapy
1/27/2012
-
Celgene to Acquire Avila Therapeutics for Up to $925 Million
1/26/2012
-
Avila Therapeutics Announces FDA Allowance of Partner Clovis Oncology’s IND Application for CO-1686, an Oral EGFR Mutant-Selective Inhibitor, Triggers $4 Million Milestone Payment to Avila
1/20/2012
-
Avila Therapeutics to Present at J.P. Morgan Healthcare Conference
1/3/2012
-
Avila Therapeutics Presents Data on AVL-292, a Selective Bruton’s Tyrosine Kinase Inhibitor, for the Treatment of B Cell Cancers at the 2011 American Society of Hematology Annual Meeting
12/12/2011
-
Avila Therapeutics to Present at the 2011American Society of Hematology Annual Meeting
12/5/2011
-
Avila Therapeutics Presents Clinical and Preclinical Data on AVL-292 Showing Potential for the Treatment of Autoimmune Disease at the 2011 American College of Rheumatology Annual Scientific Meeting
11/8/2011
-
Avila Therapeutics to Present at Lazard Capital Markets 8th Annual Healthcare Conference
11/7/2011
-
Avila Therapeutics Completes Dosing of First Patient Cohort in Phase 1b Clinical Study of AVL-292, a Selective Bruton's Tyrosine Kinase Inhibitor for the Treatment of B Cell Cancers
9/14/2011
-
Avila Therapeutics to Present at UBS Global Life Sciences Conference
9/12/2011
-
Avila Therapeutics to Present at Stifel Nicolaus 2011 Healthcare Conference
9/6/2011
-
Avila Therapeutics Moves to New, Larger Facility
8/10/2011
-
Avila Therapeutics is Granted its First U.S. Patent Covering a Class of Targeted Covalent Drugs
7/20/2011
-
Avila Therapeutics Appoints Andrew Hirsch as Chief Financial Officer
7/11/2011
-
Avila Therapeutics Presents Preclinical Data with AVL-292, its Btk Inhibitor, Demonstrating Suppression of Autoimmune Disease Activity
6/23/2011
-
Avila Therapeutics Presents Data Demonstrating the Relevance of its Btk Inhibitor, AVL-292, in B Cell Malignancies such as CLL
6/10/2011
-
Avila Therapeutics Announces Selection of Clinical Drug Candidate in EGFR Mutant-Selective Inhibitor Alliance with Clovis Oncology
6/8/2011